News

The world’s first FD treatment, Acofide demonstrated efficacy in FD patients diagnosed by the international diagnostic criteria for functional gastrointestinal diseases, the Rome III. Both the companies will

Under the agreement, a whole genome mapping module was incorporated by Applied Maths into the company’s new BioNumerics 7 software suite. With the new software tool, customers can

Indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged three months and more, Verdeso foam is emollient-based, ethanol-free and unavailable in generic form.

MOR103 has concluded Phase 1/2 development in mild to moderate rheumatoid arthritis. As per the terms of the agreement, MorphoSys will receive from GSK $29.3m (€22.5m) as immediate

Acadia CEO Uli Hacksell said that the molecule has demonstrated an attractive profile and has distinctly different properties from other glaucoma compounds advanced under the collaboration. Both the

The oral, once-daily androgen receptor inhibitor is indicated for treating metastatic castration-resistant prostate cancer patients, who were previously treated with docetaxel therapy, in the setting of medical or

Binosto, which provides fracture-risk reduction at the hip & spine, is claimed to be the first and only buffered solution used in the treatment of osteoporosis. EffRx chairman

Neutralizing a pro-inflammatory molecule known as interleukin-6 (IL-6), the new antibody is expected to represent a significant improvement compared to existing agents that have already entered clinical trials

The sale follows execution of an agreement signed between both the companies in March 2013 and marks K&F’s commitment to expand its operational presence and customer base across